Three Drug Combinations for Late-stage Trypanosoma Brucei Gambiense Sleeping Sickness: a Randomized Clinical Trial in Uganda

Overview

Journal PLoS Clin Trials

Date 2006 Dec 13

PMID 17160135

Citations 36

Authors

Gerardo Priotto

Carole Fogg

Manica Balasegaram

Olema Erphas

Albino Louga

Francesco Checchi

Salah Ghabri

Patrice Piola

Affiliations

Soon will be listed here.

Abstract

Objectives: Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense.

Design: This trial was a randomized, open-label, active control, parallel clinical trial comparing three arms.

Setting: The study took place at the Sleeping Sickness Treatment Center run by Médecins Sans Frontières at Omugo, Arua District, Uganda

Participants: Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and a total of 54 selected.

Interventions: Three drug combinations were given to randomly assigned patients: melarsoprol-nifurtimox (M+N), melarsoprol-eflornithine (M+E), and nifurtimox-eflornithine (N+E). Dosages were uniform: intravenous (IV) melarsoprol 1.8 mg/kg/d, daily for 10 d; IV eflornithine 400 mg/kg/d, every 6 h for 7 d; oral nifurtimox 15 (adults) or 20 (children <15 y) mg/kg/d, every 8 h for 10 d. Patients were followed up for 24 mo.

Outcome Measures: Outcomes were cure rates and adverse events attributable to treatment.

Results: Randomization was performed on 54 patients before enrollment was suspended due to unacceptable toxicity in one of the three arms. Cure rates obtained with the intention to treat analysis were M+N 44.4%, M+E 78.9%, and N+E 94.1%, and were significantly higher with N+E (p = 0.003) and M+E (p = 0.045) than with M+N. Adverse events were less frequent and less severe with N+E, resulting in fewer treatment interruptions and no fatalities. Four patients died who were taking melarsoprol-nifurtimox and one who was taking melarsoprol-eflornithine.

Conclusions: The N+E combination appears to be a promising first-line therapy that may improve treatment of sleeping sickness, although the results from this interrupted study do not permit conclusive interpretations. Larger studies are needed to continue the evaluation of this drug combination in the treatment of T. b. gambiense sleeping sickness.

Citing Articles

Health economic evaluation of strategies to eliminate gambiense human African trypanosomiasis in the Mandoul disease focus of Chad.

Antillon M, Huang C, Sutherland S, Crump R, Bessell P, Shaw A PLoS Negl Trop Dis. 2023; 17(7):e0011396.

PMID: 37498938 PMC: 10409297. DOI: 10.1371/journal.pntd.0011396.

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.

Kuemmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M PLoS Negl Trop Dis. 2021; 15(11):e0009903.

PMID: 34748572 PMC: 8601604. DOI: 10.1371/journal.pntd.0009903.

An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.

Kourbeli V, Chontzopoulou E, Moschovou K, Pavlos D, Mavromoustakos T, Papanastasiou I Molecules. 2021; 26(15).

PMID: 34361781 PMC: 8348971. DOI: 10.3390/molecules26154629.

Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.

Kuemmerle A, Schmid C, Kande V, Mutombo W, Ilunga M, Lumpungu I PLoS Negl Trop Dis. 2020; 14(1):e0008028.

PMID: 31986140 PMC: 7004379. DOI: 10.1371/journal.pntd.0008028.

Centering Patient Expectations of a Novel Home-Based Oral Drug Treatment among Human African Trypanosomiasis Patients in Uganda.

Lee S, Apio R, Palmer J Trop Med Infect Dis. 2020; 5(1).

PMID: 31973101 PMC: 7157203. DOI: 10.3390/tropicalmed5010016.

References

Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C . Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet. 2004; 364(9436):789-90. DOI: 10.1016/S0140-6736(04)16940-7. View

Burri C, Keiser J . Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health. 2001; 6(5):412-20. DOI: 10.1046/j.1365-3156.2001.00725.x. View

Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S . Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ. 2001; 78(11):1284-95. PMC: 2560627. View

Legros D, Evans S, Maiso F, Enyaru J, Mbulamberi D . Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 2000; 93(4):439-42. DOI: 10.1016/s0035-9203(99)90151-7. View

Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R . Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 2000; 355(9213):1419-25. DOI: 10.1016/S0140-6736(00)02141-3. View

Stanghellini A, Josenando T . The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001; 6(5):330-4. DOI: 10.1046/j.1365-3156.2001.00724.x. View

Moens F, de Wilde M, Ngato K . [Clinical trial of nifurtimox in human African trypanosomiasis]. Ann Soc Belg Med Trop. 1984; 64(1):37-43. View

Pepin J, Milord F, Khonde A, Niyonsenga T, Loko L, Mpia B . Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1995; 89(1):92-7. DOI: 10.1016/0035-9203(95)90673-8. View

Van Nieuwenhove S . Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992; 72 Suppl 1:39-51. View

10.

Eze M . Towards more efficacious chemotherapy of trypanosomiasis: combination of alpha-difluoromethylornithine (DFMO) with reactive oxygen generating drugs. Med Hypotheses. 1991; 36(3):246-9. DOI: 10.1016/0306-9877(91)90142-l. View

11.

Fairlamb A, Henderson G, Bacchi C, Cerami A . In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol. 1987; 24(2):185-91. DOI: 10.1016/0166-6851(87)90105-8. View

12.

Abeloff M, Slavik M, Luk G, Griffin C, Hermann J, Blanc O . Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol. 1984; 2(2):124-30. DOI: 10.1200/JCO.1984.2.2.124. View

13.

Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B . High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg. 1992; 86(3):254-6. DOI: 10.1016/0035-9203(92)90298-q. View

14.

JANSSENS P, De Muynck A . Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop. 1977; 57(4-5):475-80. View

15.

. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1999; 881:I-VI, 1-114. View